ghSMART | Pharma CEO Succession: Commit to a single candidate five year…

Minerva judgment

Recommendation: retain the candidate slate and converge gradually through strategy, readiness, and governance gates, as this preserves adjustability over the five-year uncertain horizon while balancing fairness and retention (F1, F2, F3, F6)

Decision owner in the teaching simulationChair of the Board CEO Succession Committee, in an independent instructional simulation

Human-controlled next action

Action: the succession committee leads development of a concrete governance-gate design proposal for the candidate slate (confidentiality, fairness, conflicts of interest, reversal thresholds) before the next board meeting

What would reverse the recommendation

Reversal condition: if evidence shows the incumbent CEO's or board's preferences (F5) have substantively driven candidate screening, rendering the slate mechanism nominal, switch to a more transparent single-path approach or restructure governance

47 · ghSMART

Watch the actual operation film

Pharma CEO Succession: Commit to a single candidate five years out, or keep a candidate slate and converge gradually using strategy, board, and readiness gates?

The Decision Room interface, case analysis, narration, captions and transcript are in English. The linked official source remains in its original language.

← Back to all 50 cases

Your browser cannot play this video. Download the MP4.Read the transcript

Official public source

ghSMART · CEO and C-suite Succession

Evidence and endorsement boundary：Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.

Inspect the evidence, then test your own decision context.

See the first-use journey Back to all 50 cases →